Status:
COMPLETED
Efficacy of Risk Assessment for Sudden Cardiac Death in Patients With Hypertrophic Cardiomyopathy
Lead Sponsor:
Poznan University of Medical Sciences
Conditions:
Hypertrophic Cardiomyopathy
Eligibility:
All Genders
18+ years
Brief Summary
Hypertrophic cardiomyopathy (HCM) is a heart disease characterized by hypertrophy of the left ventricular myocardium and is most often caused by mutations in sarcomere genes. The structural and functi...
Detailed Description
Hypertrophic cardiomyopathy (HCM) is a heart disease characterized by hypertrophy of the left ventricular myocardium and is most often caused by mutations in sarcomere genes. The structural and functi...
Eligibility Criteria
Inclusion
- Hypertrophic cardiomyopathy,
- Minimum 18 years,
- Questionnaire,
- Assessment of HCM SCD-Risk Calculator at the beginning of the observation,
- Regular visits in Cardiology Outpatient Clinic,
- Agreement to participate in the study
Exclusion
- Poorly controlled hypertension (systolic pressure on the next two visits in the Cardiology Outpatient Clinic \>180 mmHg),
- Haemodynamically significant valvular heart disease or valve replacement condition,
- Past myocardial infarction (haemodynamically significant changes found in coronarography),
- Heart transplant,
- Insufficient amount of data from the subject and additional tests allowing for further analysis,
- Lack of consent to participate in the study.
Key Trial Info
Start Date :
October 1 2014
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
February 28 2019
Estimated Enrollment :
252 Patients enrolled
Trial Details
Trial ID
NCT04402268
Start Date
October 1 2014
End Date
February 28 2019
Last Update
May 26 2020
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Poznan Univeristy of Medical Sciences
Poznan, Wielkopolska, Poland, 61-848